Masanori Fukushima

Prof. Dr. Masanori Fukushima

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Nutrition
Verified
Journal Article
Open access
SKShinichiro Kodama
Shinichiro Kodama
NKNafuko Konishi
Nafuko Konishi
YHYuriko Hirai
Yuriko Hirai
AFAkinori Fujisawa
Akinori Fujisawa
MNMitsuko Nakata
Mitsuko Nakata
MFMasanori Fukushima
Masanori Fukushima
Prolonged symptoms have been reported following both COVID-19 infection and vaccination, with some cases leading to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Of 80 patients presenting to our hospital with postvaccination syndrome, 28 met the diagnostic criteria for ME/CFS. We conducted a retrospective study on these 28 patients. We measured serum 25-hydroxyvitamin D levels in 28 patients who developed ME/CFS after COVID-19 vaccination between August 2022 and February 2024. Vitamin D replacement therapy included dietary counseling, sun exposure recommendations, and oral vitamin D supplementation. We evaluated changes in blood vitamin D levels and symptom improvement. At initial visit, 27 of 28 patients diagnosed with ME/CFS had insufficient or deficient serum 25-hydroxyvitamin D levels (16 ± 4 ng/mL, mean ± SD). Following vitamin D replacement therapy, we observed an increase in blood vitamin D levels (28 ± 5 ng/mL) associated with a decrease in ME/CFS diagnostic symptoms (from 10.3 ± 2.1 to 3.3 ± 2.0). Notably, 23 of 28 patients (82%) no longer met ME/CFS diagnostic criteria after the therapy. Among the symptoms, sleep problems showed the most improvement (71%), followed by autonomic symptoms (68%). For patients developing ME/CFS after COVID-19 vaccination with insufficient or deficient vitamin D levels, appropriate vitamin D replacement therapy under medical guidance may lead to symptomatic relief. We are preparing a randomized controlled trial to evaluate the efficacy of vitamin D replacement therapy in individuals with ME/CFS who have developed vitamin D deficiency following COVID-19 infection or vaccination.

3 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
慎児慎一郎 児玉
慎一郎 児玉
MNMitsuko Nakata
Mitsuko Nakata
NKNafuko Konishi
Nafuko Konishi
MYMasato Yoshino
Masato Yoshino
AFAkinori Fujisawa
Akinori Fujisawa
MFMasanori Fukushima
Masanori Fukushima
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can develop as post-vaccination syndrome (PVS) or Post-Acute Sequelae of SARS-CoV-2 infection (PASC). In our prior retrospective study, most patients with PVS who developed ME/CFS had vitamin D insufficiency or deficiency. We evaluated the efficacy of vitamin D replacement therapy guidance for ME/CFS symptom improvement in patients with vitamin D insufficiency or deficiency. Methods: This open-label randomized controlled trial enrolled 91 participants with ME/CFS as PVS or PASC and serum 25(OH) vitamin D < 30 ng/mL across five clinical sites. Participants were randomized 1:1 to intervention (active vitamin D preparation plus vitamin D replacement therapy guidance: 25 μg daily supplementation, dietary counseling, sun exposure, and exercise) or control (active vitamin D preparation alone) for 12 weeks. The primary endpoint was the change in ME/CFS symptom count from screening to Week 12. Results: Mean symptom change was −6.7 in the intervention group versus −1.2 in the control group (between-group difference −5.6; 95% CI: −7.2, −3.9; p < 0.001). Serum 25(OH) vitamin D improved from 18.6 to 27.1 ng/mL in the intervention group, while the control group showed a decreasing trend (between-group difference 10.2 ng/mL; 95% CI: 7.9, 12.5). Achievement of <8 symptoms (i.e., no longer meeting ME/CFS diagnostic criteria) was significantly higher in the intervention group, with 16 participants achieving this threshold compared to 1 in the control group (p < 0.001). Subgroup analyses showed consistent benefit in both PVS (n = 56) and PASC (n = 29) cohorts. Conclusions: Vitamin D replacement therapy guidance significantly reduced ME/CFS symptoms along with improvement of serum 25(OH) vitamin D levels in patients with vitamin D insufficiency or deficiency who developed ME/CFS as PVS or PASC.

29 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JUJun Ueda
Jun Ueda
HMHideyuki Motohashi
Hideyuki Motohashi
YHYuriko Hirai
Yuriko Hirai
KYKenji Yamamoto
Kenji Yamamoto
YMYasufumi Murakami
Yasufumi Murakami
AFAkinori Fujisawa
Akinori Fujisawa
The World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic in 2020, following which a global genetic vaccination program has been rapidly implemented as a fundamental solution. However, it has been reported worldwide that the modified mRNAs encoding spike proteins and lipid nanoparticles, which are used as drug delivery systems, not only cause thrombosis and cardiovascular disorders post vaccination, but might also cause diverse diseases involving all organs and systems, including the nervous system. Furthermore, the toxicity and pathogenicity of spike proteins may necessitate defining these proteins as nonbiological infective material. Based on these reports and the abundant evidence that has come to light in the past few years, this paper aims to draw the attention of medical professionals to the various risks associated with transfusion using blood products derived from long COVID patients or from genetic vaccine recipients, and to make proposals regarding specific inspection items, testing methods, regulations, etc. This paper provides insights to address the post-vaccination syndrome and its consequences following such genetic vaccination programs.

1 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
PGPatrizia Gentilini
Patrizia Gentilini
JLJanci Chunn Lindsay
Janci Chunn Lindsay
NKNafuko Konishi
Nafuko Konishi
MFMasanori Fukushima
Masanori Fukushima
Panagis PolykretisPanagis Polykretis
Panagis Polykretis
In this report we describe the case of a healthy, young, athletic woman who developed acute lymphoblastic leukaemia (ALL)/lymphoblastic lymphoma (LBL) after receiving the second dose of the Pfizer/BioNTech modified mRNA (modRNA) COVID-19 genetic vaccine (marketed as Comirnaty®). The first dose of the genetic vaccine did not appear to illicit any noticeable side effects, but within 24 hours of the second dose the patient suffered widespread and intensifying bone pain, fever, vomiting, and general malaise. Due to the persistence of the symptoms, the patient underwent a series of tests and examinations including a full laboratory workup, a consult with a clinical immunologist and rheumatologist, a Positron Emission Tomography (PET) imaging, as well as an osteomedullary biopsy. These together led to a definitive diagnosis of ALL. A time interval of 16 weeks from the second vaccination to the diagnosis of cancer was noted. Several similar cases with identical pathology which developed after the modRNA COVID-19 vaccination, are described in case reports in the scientific literature. The massive and indiscriminate use of genetic vaccines to fight COVID-19 is raising serious concerns about their safety and about the technology platform as a whole for this purpose. Growing evidence is accumulating regarding the biodistribution and persistence of the modRNA which can reach, thanks to the lipid nanoparticles, a multitude of tissues and organs of the body, including the bone marrow and other blood-forming organs and tissues. Moreover, there is evidence that the modRNA vaccines display a particular tropism for the bone marrow, influencing the immune system at multiple levels and being able to trigger not only autoimmune-based pathologies, but also neoplastic mechanisms. The aim of this article is to assess, on the basis of the available scientific literature, the risk of developing haematopoietic cancers after modRNA vaccination, and to investigate the potential genetic mechanisms involved in the pathogenesis of disease.

26 May 2026 in Cells
Verified
Journal Article
Open access
PDF file
MMMichael Mörz
Michael Mörz
ADAlberto Donzelli
Alberto Donzelli
RCRobert Llewellyn Clancy
Robert Llewellyn Clancy
SSShigetoshi Sano
Shigetoshi Sano
MFMasanori Fukushima
Masanori Fukushima
Panagis PolykretisPanagis Polykretis
Panagis Polykretis
The rapid development and deployment of COVID-19 genetic vaccines have raised significant concerns regarding their safety and potential to trigger immune reactions against self-tissues. This paper provides a comprehensive histopathologically supported analysis of how the synthesis of the vaccine-derived spike protein can trigger such reactions beyond the injection site, characterized by robust immune cell recruitment. We examine these immune responses based on histopathological evidence that delineates a pattern consistent with self-directed immune activity, including vaccine-associated myocarditis. In this regard, we report two representative cases, marked by immune-cell infiltration, triggered by the synthesis of the vaccine-derived spike protein in the myocardium and in the liver, respectively. Additionally, we provide a detailed characterization of the process and the immune cells involved in these reactions, based on histopathological findings. Understanding these mechanisms is essential for accurately assessing the potential implications of these vaccination technologies on human health. By emphasizing the need for further research into the pharmacokinetics and off-target effects of COVID-19 genetic vaccines, this paper aims to deepen our understanding of their safety profiles and inform future vaccine development.

1 January 2025 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
HSHiroaki Shimokawa
Hiroaki Shimokawa
MAMasahiro Akishita
Masahiro Akishita
TATakashi Asada
Takashi Asada
SKSadao Katayama
Sadao Katayama
YHYorito Hattori
Yorito Hattori
MFMasanori Fukushima
Masanori Fukushima
Background: We demonstrated that low-intensity pulsed ultrasound (LIPUS) therapy tended to ameliorate cognitive declines in patients with early Alzheimer's disease (AD) in the pilot trial. Thus, we have started the pivotal trial in a randomized, double-blind, placebo-controlled manner (LIPUS-AD). Objective: We here report the clinical characteristics of AD patients enrolled in the trial. Methods: The major inclusion criteria included age 50–90 years of both sex, Clinical Dementia Rating (CDR) global score of 0.5∼1.0 and Japanese version of the Mini-Mental State Examination (MMSE-J) score greater than 20 at screening, positive brain Aβ-PET, and no symptomatic brain hemorrhage, infarction, or edema on brain MRI. Results: A total of 231 subjects were finally enrolled. As compared with the pilot trial, they were characterized by older age and higher prevalence of dyslipidemia. They had lower scores of ADAS-J-cog and Modified Hachinski Ischemic Scale (MHIS), while other cognitive scores were comparable with the pilot trial. Use of cholinesterase inhibitors was less as compared with the pilot trial. APOE ε4 polymorphism is present in 58% of the subjects, including heterozygote in 44% and homozygote in 14%. Brain MRI measurements showed that hippocampus volume was distributed with a peak at 5700–5999 mm 3 without left and right difference, and brain Aβ-PET showed that centiloid scale distributed with a peak at 90–99.9 and standardized uptake value ratio (SUVR) with a peak at 0.7–0.79. There were weak but significant correlations between ADAS-J-cog14 and those brain MRI and Aβ-PET measurements. Conclusions: Clinical characteristics of subjects in the LIPUS-AD trial largely mimic those in the pilot trial, addressing efficacy and safety of the LIPUS therapy in early AD. Clinical Trial Gov. No.: NCT05983575, jRCT No.: jRCT2032230125